Back to top
more

Mesa Laboratories (MLAB)

(Delayed Data from NSDQ)

$106.90 USD

106.90
31,589

-4.13 (-3.72%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $106.11 -0.79 (-0.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for MLAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 28 33 49 264 81
Receivables 39 43 41 24 21
Notes Receivable NA 0 0 0 0
Inventories 33 35 25 11 14
Other Current Assets 9 9 9 5 6
Total Current Assets 109 119 124 304 123
Net Property & Equipment 32 28 29 22 22
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 1 1 1 1 11
Intangibles 294 503 541 273 261
Deposits & Other Assets 11 10 12 3 2
Total Assets 447 662 707 601 420
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable 6 6 8 4 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses 23 23 26 18 15
Income Taxes Payable NA 0 0 2 0
Other Current Liabilities 15 14 14 9 7
Total Current Liabilities 44 43 48 33 26
Mortgages NA 0 0 0 0
Deferred Taxes/Income 20 34 39 16 33
Convertible Debt 171 170 169 146 140
Long-Term Debt 51 13 49 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 16 8 8 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 301 268 314 195 200
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) 344 332 313 318 158
Capital Surplus NA 0 0 0 0
Retained Earnings -183 74 77 72 72
Other Equity -15 -13 4 16 -10
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 145 393 394 406 220
Total Liabilities & Shareholder's Equity 447 662 707 601 420
Total Common Equity 100,144 393 394 406 220
Shares Outstanding 5.30 5.30 5.20 5.10 4.30
Book Value Per Share 18,895.17 74.24 75.73 79.65 51.17

Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,971 28 36 32
Receivables NA 39 36 36 36
Notes Receivable NA NA 0 0 0
Inventories NA 33 36 33 36
Other Current Assets NA 9 18 13 11
Total Current Assets NA 109 118 118 115
Net Property & Equipment NA 32 32 29 28
Investments & Advances NA NA 0 0 0
Other Non-Current Assets NA NA 0 0 0
Deferred Charges NA 1 1 1 1
Intangibles NA 294 579 481 489
Deposits & Other Assets NA 11 12 9 10
Total Assets NA 447 742 637 643
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 0 0
Accounts Payable NA 6 5 5 6
Current Portion Long-Term Debt NA NA 0 0 0
Current Portion Capital Leases NA NA 0 0 0
Accrued Expenses NA 23 25 21 18
Income Taxes Payable NA NA 0 0 0
Other Current Liabilities NA 15 14 14 15
Total Current Liabilities NA 44 44 40 39
Mortgages NA NA 0 0 0
Deferred Taxes/Income NA 20 44 33 34
Convertible Debt NA 171 171 171 171
Long-Term Debt NA 51 62 0 5
Non-Current Capital Leases NA NA 0 0 0
Other Non-Current Liabilities NA 17 5 7
Minority Interest (Liabilities) NA NA 0 0 0
Total Liabilities NA 301 339 249 255
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 0 0
Common Stock (Par) NA 344 341 338 334
Capital Surplus NA NA 0 0 0
Retained Earnings NA -183 72 71 73
Other Equity NA -15 -10 -21 -19
Treasury Stock NA NA 0 0 0
Total Shareholder's Equity NA 145 403 388 388
Total Liabilities & Shareholder's Equity NA 447 742 637 643
Total Common Equity 0 100,144 403 388 388
Shares Outstanding 5.40 5.30 5.30 5.30 5.30
Book Value Per Share 0.00 18,895.17 76.03 73.16 73.15